Axis Biotec Brasil

What Axis Biotec Brasil does

Axis Biotec Brasil is a family-led biotechnology group headquartered in Rio de Janeiro, Brazil, operating an integrated ecosystem of four wholly-owned subsidiaries: Silvestre Labs (pharmaceutical dermatological products including Dermazine, Colzen, and Dermacerium for hard-to-heal wounds), Cryopraxis (cryopreservation services and Brazil's largest stem cell bank with 50,000+ preserved biological samples), CellPraxis (GMP-certified manufacturing of Advanced Therapy Products including gene therapy, cell therapy, and tissue engineering under ANVISA authorization), and BioNK (R&D into NK cell-based immunotherapy for oncology). The group originated from research begun by Luís Eduardo da Cruz in 1984 at the Andaraí Hospital Burn Center, with Silvestre Labs formally founded in 1986; Cryopraxis was established in the 2000s and CellPraxis in the 2010s, with all four entities formally integrated as Axis Biotec Brasil in 2024-2026.

The underlying technology stack combines patented pharmaceutical formulations, proprietary ReACT technology, GMP-certified cell processing infrastructure, cryopreservation logistics with liquid nitrogen storage at -196°C, bioprocess engineering for Critical Quality Attributes, and extracellular vesicle processing aligned to MISEV guidelines. The group holds AABB Accreditation (Cryopraxis) and ANVISA Cell Processing Center authorization (CellPraxis), and is recognized via FINEP and FAPESP innovation awards.

The business model is multi-stream: one-time pharmaceutical product sales (Silvestre Labs), recurring subscription revenue from cryopreservation storage and cord blood banking (Cryopraxis), professional services for GMP ATP manufacturing and clinical research support (CellPraxis), and longer-horizon licensing/royalty potential from NK cell immunotherapy R&D (BioNK). GTM is primarily direct B2B field sales to healthcare institutions, hospitals, and burn centers, supplemented by channel distribution for pharmaceuticals and direct-to-consumer cord blood banking. Operations are currently Brazil-domestic, with a stated vision of consolidating as an Ibero-American reference. Pricing is not publicly disclosed.

Name

Axis Biotec Brasil

Legal name

Axis Biotec Brasil

Website

https://axisbiotec.com.br

Company type

Private

Founded year

1986

Operating status

Operating

Headcount range

1–10 employees

Short description

Axis Biotec Brasil is a family-led Rio de Janeiro biotechnology ecosystem integrating four subsidiaries (Silvestre Labs, Cryopraxis, CellPraxis, BioNK) across topical wound therapy, stem cell cryopreservation, GMP advanced therapy manufacturing, and NK cell immunotherapy research, serving Brazilian healthcare institutions and specialty providers.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)

akta.pro secondary industries

Cryopreservation, Biobanking & Cell Banking (Cord/Adipose/MSC) (HLAMANAJ), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Dermatology Specialty Pharmaceuticals (HLAIACAL)

Keywords

• Pharmaceutical manufacturing
• Cryopreservation services
• Advanced therapy products
• Stem cell banking
• Regenerative medicine

Headquarters

HQ city

Rio de Janeiro

HQ country

Brazil

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Products (Silvestre Labs): Manufacture and sale of pharmaceutical dermatological products including Dermazine, Colzen, and Dermacerium for wound healing and tissue repair. Products serve healthcare providers and patients requiring topical therapy for hard-to-heal wounds.
2. Cryopreservation Services (Cryopraxis): Cryopreservation and cell logistics services for stem cells and biological materials. Brazil's largest stem cell bank. Revenue from storage fees and processing services for cord blood, tissues, and biological materials.
3. Advanced Therapy Products (CellPraxis): Development and manufacturing of ATPs including gene therapy, cell therapy, and tissue engineering products per ANVISA regulations. Services include clinical research support and GMP manufacturing for regenerative medicine applications.
4. NK Cell Immunotherapy R&D (BioNK): Research and development of NK cell-based immunotherapy strategies focused on oncology applications. Pipeline development with emphasis on safety and evidence-based approaches.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Axis Biotec Brasil is an integrated biotechnology ecosystem operating four specialized subsidiaries: Silvestre Labs develops and manufactures topical dermatological pharmaceuticals including Dermazine, Colzen, and Dermacerium for wound healing and tissue repair; Cryopraxis provides certified cryopreservation services and operates Brazil's largest stem cell bank with 50,000+ preserved samples; CellPraxis develops and manufactures Advanced Therapy Products (ATPs) including gene therapy, cell therapy, and tissue engineering under GMP conditions per ANVISA regulations; BioNK conducts R&D on NK cell-based immunotherapies for oncology applications.

Product overview

Axis Biotec Brasil is a biotechnology ecosystem composed of four specialized subsidiary companies operating as an integrated portfolio. Silvestre Labs is the pharmaceutical arm developing topical wound therapy products (Dermazine, Colzen, Dermacerium). Cryopraxis provides cryopreservation services and operates Brazil's largest stem cell bank. CellPraxis manufactures Advanced Therapy Products (ATPs) including gene therapy, cell therapy, and tissue engineering under GMP conditions. BioNK conducts R&D on NK cell-based immunotherapy for oncology. The ecosystem also includes patented technologies such as ReACT and proprietary formulations like Colzen. The companies share infrastructure, scientific expertise, and regulatory standards, enabling integrated translation from research through clinical application.

Differentiator

Problem solved

Functional benefit

Brands

• Silvestre Labs: Develops and manufactures pharmaceutical products for topical therapy of hard-to-heal wounds
• Cryopraxis
• CellPraxis
• BioNK

Products and services

• Dermazine Dermatological pharmaceutical solution developed for wound healing and tissue repair. Reference product for burns and surgical wounds created by Luís Eduardo da Cruz; manufactured by Silvestre Labs under certified quality and dermatological product line.
• Colzen Patented pharmaceutical formulation from Silvestre Labs for skin care and cutaneous repair, part of the dermatological product line dedicated to healing and tissue care.
• Dermacerium Topical formulation for wound treatment and healing support developed as part of Silvestre Labs' dermatological pharmaceutical line.
• Cryopreservation Services Certified cryopreservation services for stem cells and biological materials operated by Cryopraxis, Brazil's largest stem cell bank with 50,000+ preserved samples under AABB international quality standards, including storage at -196°C in liquid nitrogen.
• Private Cord Blood Banking Private cord blood and stem cell banking services from Cryopraxis for families seeking biological material preservation for potential future therapeutic use, with AABB-accredited quality standards.
• Advanced Therapy Products (ATPs) GMP-manufactured Advanced Therapy Products including gene therapy, cell therapy, and tissue engineering, produced by CellPraxis under ANVISA authorization as a certified Cell Processing Center, supporting clinical research and bioprocess development for cell-based products.

Quantifiable outcome

• 50,000+ preserved biological samples under certified quality standards
• +1 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Pluristem Therapeutics: Clinical-stage cell therapy company developing placenta-derived allogeneic cell therapies for inflammatory and ischemic conditions; comparable to CellPraxis/BioNK as an emerging peer in regenerative cell therapy with GMP manufacturing focus.

Direct peers

• Cordvida: Brazilian cord blood and stem cell bank offering private family banking and tissue storage; directly comparable to Cryopraxis as a domestic competitor in Brazilian stem cell banking and biological material cryopreservation.
• Cellavita: Brazilian cell therapy company developing autologous and allogeneic cell-based products for regenerative medicine and immunology; comparable to CellPraxis/BioNK as a domestic cell therapy peer operating under ANVISA ATP regulation.
• Hemocord: Brazilian stem cell and umbilical cord blood bank; comparable to Cryopraxis as a peer in the domestic cord blood banking and cellular storage market.

Regional players

• Eurofarma Laboratórios: One of Brazil's largest pharmaceutical companies with diversified dermatology, prescription and OTC portfolios; comparable to Silvestre Labs as a regional peer in Brazilian dermatological/wound care pharmaceuticals with broader commercial scale.
• Aché Laboratórios: Major Brazilian pharmaceutical manufacturer with a significant dermatology and skin care franchise; comparable to Silvestre Labs as a domestic peer in topical pharmaceutical products with established Brazilian distribution.

Broad incumbents

• Mesoblast: Clinical-stage cell therapy developer focused on allogeneic mesenchymal lineage and immunomodulatory cell therapies; comparable to BioNK/CellPraxis as a broader incumbent pursuing commercial-stage cell therapy indications.
• Catalent: Global CDMO providing cell therapy, gene therapy and biologics manufacturing services at scale; comparable to CellPraxis as an incumbent offering similar GMP manufacturing capabilities as part of a much broader services portfolio.
• Smith+Nephew: Global medical device company with a major Advanced Wound Management franchise; comparable to Silvestre Labs as a broader incumbent in the wound healing and skin repair category with much larger geographic reach.
• Lonza Group: Global leading contract development and manufacturing organization (CDMO) for biologics and cell and gene therapies; comparable to CellPraxis as a broader incumbent in the same GMP cell therapy manufacturing space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/axis-biotec-brasil

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Axis Biotec Brasil